The recent advent of molecularly targeted therapies such as IDH1/IDH2/FLT3 inhibitors and the incorporation of the BCL-2 inhibitor Venetoclax in newly diagnosed AML patients have resulted in enhancements in progression-free survival (PFS) and overall survival (OS). This evidence concerns the gene FLT3 and acute myeloid leukemia.